[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100226772":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":34,"collaborators":11,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":11,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":11,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":11,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":11,"leadSponsor":62,"locationsCount":11},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Meloxicam suspension","EXPERIMENTAL",null,[13],"Drug: Meloxicam",{"label":15,"type":16,"description":11,"interventionNames":17},"Diclofenac suspension","ACTIVE_COMPARATOR",[18],"Drug: Diclofenac",{"label":20,"type":16,"description":11,"interventionNames":21},"Nimesulide suspension",[22],"Drug: Nimesulide",[24,28,31],{"type":25,"name":26,"description":11,"armGroupLabels":27,"otherNames":11},"DRUG","Meloxicam",[9],{"type":25,"name":29,"description":11,"armGroupLabels":30,"otherNames":11},"Diclofenac",[15],{"type":25,"name":32,"description":11,"armGroupLabels":33,"otherNames":11},"Nimesulide",[20],{"type":35,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100226772","phase-4-efficacy-and-safety-of-meloxicam-suspension-versus-diclofenac-suspension-or-nimesulide-suspension-in-patients-with-a-diagnosis-of-acute-non-bacterial-pharyngitis-pharyngotonsillitis-or-laryngitis-100226772",false,"NCT02229747","Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis","Randomized, Open-label, Controlled Trial to Assess the Clinical Efficacy and Safety of Meloxicam Suspension 0.25 mg\u002Fkg\u002FDay Once a Day, Versus Diclofenac 1 mg\u002Fkg\u002FDay Twice a Day or Nimesulide 4 mg\u002Fkg\u002FDay Twice a Day, for Five Days in the Treatment of Patients With Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis","Inclusion Criteria:\n\n* Patients of both genders between 2 and 8 years old\n* Outpatients, with onset of symptoms not more than 72 hours prior to presentation, patients with acute non-bacterial pharyngitis or pharyngotonsillitis diagnosed according to the following criteria:\n\n  * Spontaneous pharyngeal pain, pharyngeal pain upon swallowing, pharyngeal and\u002For tonsillar hyperemia, absence of purulent plaques, pharyngeal smear negative for ß-hemolytic Streptococcus or Strepto Test® and Treatment with an Non-steroidal anti-inflammatory drugs (NSAID) required or recommended\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study medications or NSAID's\n* Pharyngeal smear positive for ß-hemolytic Streptococcus\n* treatment with antimicrobials prior to enrolment in the study\n* Chronic infection, infectious mononucleosis, peptic ulcer disease that has been active in the previous 6 months\n* Asthma\n* nasal polyps\n* angioneurotic edema or urticaria after the administration of aspirin or NSAID's\n* Concomitant treatment with anticoagulants (including heparin), lithium or methotrexate\n* Concomitant administration of other NSAID's (including high dose aspirin) or analgesics, except authorized rescue drugs\n* Administration of any NSAID during the three previous days or of analgesics within six hours prior to the administration of the first study drug dose\n* Treatment with corticosteroids at the time of enrollment or within the two previous months\n* Known liver, renal or hematological disease\n* Participation in another clinical trial during the study period or during the previous month\n* Previous enrollment in this study\n* Inability to comply with the protocol\n* Suspected acute bacterial pharyngitis or pharyngotonsillitis (under the following clinical criteria):\n\n  * Clinical presentation characterized by a rapid onset, very high fever (\\>38.5°C), severe pharyngeal pain, cervical adenopathy, intense headache, purulent pharyngeal plaques, evidence of peritonsillar abscess or phlegmon","ALL","2 Years","8 Years",{"count":47,"type":48},128,"ACTUAL","INTERVENTIONAL",[51],"PHASE4","The objective of this study was to assess the clinical efficacy and safety of meloxicam suspension 0.25 mg\u002Fkg\u002Fday once a day, versus diclofenac suspension 1 mg\u002Fkg\u002Fday twice a day or nimesulide suspension 4 mg\u002Fkg\u002Fday twice a day, after five days of treatment in patients with a diagnosis of acute, non-bacterial pharyngitis, pharyngotonsillitis or laryngitis",[54],"Pharyngitis","COMPLETED","2014-08-29",{"date":58,"type":59},"2014-09-01","ESTIMATED",{"date":61,"type":11},"2001-08",{"name":5,"class":6}]